Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
Clara Sortais, Anne Lok, Benoît Tessoulin, Thomas Gastinne, Beatrice Mahé, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Anne Moreau, Céline Bossard, Pierre Péterlin, Alice Garnier, Thierry Guillaume, Amandine Le Bourgeois, Patrice Chevallier, Philippe Moreau, Christophe Leux, Steven Le Gouill
Topics & Concepts
Follicular lymphomaMedicineInternal medicineRituximabPrednisoneCohortLymphomaVincristineRetrospective cohort studyOncologyCyclophosphamideChemotherapyLymphoma Diagnosis and TreatmentViral-associated cancers and disordersOvarian cancer diagnosis and treatment